Vor Biopharma (NASDAQ:VOR) Director Sells $2,455,147.95 in Stock

Vor Biopharma Inc. (NASDAQ:VOR) Director Ra Capital Management, L.P. sold 153,735 shares of the company’s stock in a transaction dated Tuesday, April 14th. The shares were sold at an average price of $15.97, for a total transaction of $2,455,147.95. Following the completion of the transaction, the director directly owned 3,251,263 shares in the company, valued at $51,922,670.11. The trade was a 4.51% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Monday, April 13th, Ra Capital Management, L.P. sold 530,610 shares of Vor Biopharma stock. The shares were sold at an average price of $16.15, for a total transaction of $8,569,351.50.
• On Wednesday, April 15th, Ra Capital Management, L.P. sold 53,644 shares of Vor Biopharma stock. The shares were sold at an average price of $16.01, for a total transaction of $858,840.44.
• On Friday, April 10th, Ra Capital Management, L.P. sold 828 shares of Vor Biopharma stock. The shares were sold at an average price of $15.75, for a total transaction of $13,041.00.
• On Thursday, April 9th, Ra Capital Management, L.P. sold 135,201 shares of Vor Biopharma stock. The shares were sold at an average price of $16.59, for a total transaction of $2,242,984.59.
• On Wednesday, April 8th, Ra Capital Management, L.P. sold 484,104 shares of Vor Biopharma stock. The shares were sold at an average price of $16.48, for a total transaction of $7,978,033.92.
• On Monday, April 6th, Ra Capital Management, L.P. sold 589,257 shares of Vor Biopharma stock. The shares were sold at an average price of $16.59, for a total transaction of $9,775,773.63.
• On Thursday, April 2nd, Ra Capital Management, L.P. sold 260,000 shares of Vor Biopharma stock. The shares were sold at an average price of $18.23, for a total transaction of $4,739,800.00.

Vor Biopharma Price Performance

NASDAQ VOR opened at $16.59 on Friday. The firm’s 50-day moving average is $14.72 and its two-hundred day moving average is $16.51. Vor Biopharma Inc. has a 12 month low of $2.62 and a 12 month high of $65.80. The stock has a market capitalization of $810.42 million, a P/E ratio of -0.04 and a beta of 1.92.

Vor Biopharma News Roundup

Here are the key news stories impacting Vor Biopharma this week:

• Positive Sentiment: HC Wainwright materially raised forward EPS estimates (Q1–Q4 2026 and FY2026–2029), cutting projected losses for 2026–2028 and now forecasting FY2029 EPS of $4.16; the firm keeps a “Buy” rating and $31 price target — this reduces near‑term downside in forecasts and signals brighter long‑term expectations. HC Wainwright research note
• Neutral Sentiment: Broader Wall Street coverage remains mixed-to-positive: multiple firms have buy/overweight ratings while several maintain holds; the MarketBeat consensus target remains well above the current price, implying analyst upside but with dispersion in conviction. Analyst coverage summary
• Neutral Sentiment: Institutional ownership is high (reported ~97% held by institutions) and some new stakes were disclosed recently; that concentration can amplify moves but also means flow changes (in or out) matter more than usual. Institutional holdings update
• Negative Sentiment: Ra Capital Management, L.P. (a director-level holder) has been an active seller in April, unloading multiple tranches (including >500k shares on Apr 13 and additional sales on Apr 2–15), trimming its position materially — this large insider selling increases supply and is likely weighing on sentiment. SEC Form 4 — Ra Capital sales Coverage of Ra Capital sales

Institutional Trading of Vor Biopharma

Large investors have recently made changes to their positions in the company. Ariose Capital Management Ltd purchased a new stake in shares of Vor Biopharma during the third quarter worth approximately $5,368,000. Fcpm Iii Services B.V. purchased a new stake in shares of Vor Biopharma during the third quarter worth approximately $18,496,000. Susquehanna Portfolio Strategies LLC purchased a new stake in shares of Vor Biopharma during the fourth quarter worth approximately $134,000. XTX Topco Ltd purchased a new stake in shares of Vor Biopharma during the second quarter worth approximately $66,000. Finally, Goldman Sachs Group Inc. increased its stake in shares of Vor Biopharma by 218.2% during the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock worth $61,000 after buying an additional 58,247 shares during the period. 97.29% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

VOR has been the topic of a number of recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vor Biopharma in a research note on Wednesday, January 21st. Wedbush boosted their price target on shares of Vor Biopharma to $15.00 and gave the stock a “neutral” rating in a research note on Tuesday, March 31st. Wall Street Zen upgraded shares of Vor Biopharma from a “strong sell” rating to a “hold” rating in a research note on Saturday, April 4th. Wells Fargo & Company initiated coverage on shares of Vor Biopharma in a research note on Thursday, March 19th. They set an “overweight” rating and a $30.00 price target on the stock. Finally, HC Wainwright cut their price target on shares of Vor Biopharma from $32.00 to $31.00 and set a “buy” rating on the stock in a research note on Wednesday. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Vor Biopharma currently has a consensus rating of “Moderate Buy” and an average target price of $50.56.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).